Gene therapy biotech Solid Biosciences sets terms for $100 million IPONasdaqSolid Biosciences, which is developing a gene therapy to treat Duchenne muscular dystrophy (DMD), announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans … Continue reading
FierceBiotech |
AveXis steps up gene therapy pursuit of Biogen’s SMA pathfinder
FierceBiotech AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) with a series of new trials as it plays catch-up with Biogen and Ionis, which claimed the first approval for an SMA drug. The Chicago biotech already has … AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular AtrophyMarkets Insider AveXis (NASDAQ:AVXS) PT Set at $122.00 by UBS GroupThe Lincolnian Online Chardan Capital Reiterates Buy Rating for AveXis (NASDAQ:AVXS)StockNewsTimes |
The Globe and Mail |
Canadian researchers test new stem–cell therapy for diabetes
The Globe and Mail A Vancouver man with Type 1 diabetes is the first Canadian to receive an experimental stem–cell therapy aimed at restoring the body’s ability to produce insulin, researchers at the University of British Columbia announced Tuesday. Last month, the … Stem cell implant trial aims to reverse Type 1 diabetesVancouver Sun |
Genetic Literacy Project |
CRISPR could be the answer to genetic engineering’s prayers
Genetic Literacy Project And, in fact, it was in this manner – as a bacteria’s defense against invading viruses – that the CRISPR-Cas process first emerged. [S]cientists have figured out how to replicate the process [of viral infection], enabling humans to edit, with the … |